Neuland Laboratories Limited has released its financial results for the second quarter and the first half of the fiscal year 2027. The presentation details key financial highlights, segment performance, and strategic priorities. The company emphasizes its continued growth expectations and investments in capabilities for future expansion. The report also includes a comprehensive overview of its business verticals, manufacturing facilities, R&D strengths, and global presence.
Neuland Laboratories Q2FY27 and H1FY27 Investor Presentation
Neuland Laboratories Limited has published its investor presentation for the quarter and half year ended September 30, 2026. The presentation covers the company’s performance during Q2FY27 and H1FY27, offering insights into its financial health and operational achievements.
Management Commentary and Financial Highlights
SAHARSH DAVULURI, CEO & MD, noted that while Q2FY27 saw a dip in performance, H1 FY27 was largely in line with plans. Growth expectations for FY27 and the following year remain intact. Commercial CMS molecules are driving near-term growth, supported by strong RFP activity and progress with Big Pharma. Investments in peptides, R&D, and land acquisition are strengthening capabilities for agile expansion.
Q2FY27 Performance
Standalone revenue for Q2FY27 decreased by 11.4% YoY to ₹457.2 Cr. EBITDA stood at ₹104.6 Cr, with an EBITDA margin of 22.9%, down 754 bps YoY, attributed to operating deleverage. Profit After Tax (PAT) for the quarter was ₹51.1 Cr, a decrease of 47.0% YoY, with a PAT margin of 11.2%. Diluted EPS was ₹39.9.
H1FY27 Performance
Total income for H1FY27 reached ₹1107.2 Cr, marking a 35.6% YoY increase. EBITDA for H1FY27 was ₹335.6 Cr, a substantial 68.6% YoY growth. The EBITDA Margin improved to 30.3%, an increase of 594 bps YoY. PAT for H1FY27 was ₹198.5 Cr, up 80.2% YoY.
Key Balance Sheet and Operating Metrics
Key balance sheet metrics for H1FY27 include a Current Ratio of 2.2, ROCE% of 24.3%, Fixed Asset Turnover Ratio of 2.4, and Debt to Equity of 0.12. The company’s Net Debt stood at ₹(208.0) Cr as of September 2026.
Operating metrics for Q2FY27 show segment revenues with ‘Others’ at 8%, CMS at 53%, Specialty at 10%, and Prime at 30%. The company also highlighted its position in the Top 10 & Top 5 Products and Customers across its business segments.
Business Verticals: GDS and CMS
Neuland operates in two primary business verticals: Generic APIs (GDS) and CDMO Services (CMS).
- Generic APIs (GDS): The company is a preferred provider for Active Pharmaceutical Ingredients (APIs), with a heritage of over 40 years in API manufacturing. It offers flexible capacity from 100g to hundreds of tons and has a worldwide customer base in over 80 countries.
- CDMO Services (CMS): This segment focuses on cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply. It involves capabilities such as process optimization, designing manufacturing processes, and IND/NDA filing support.
Key Milestones and Global Presence
The company has a long history, starting from its foundation in 1984, with significant milestones including R&D center establishment in 2008, crossing INR 10 bn revenue in 2023, and planning for a new Peptide Facility operational in 2026. Neuland has successfully cleared 18 USFDA inspections. Its global presence is distributed with 63% of revenue from Europe, 31% from North America, and smaller percentages from APAC, Japan, LATAM, MENA, and India. It serves customers in over 80 countries.
Manufacturing and R&D Capabilities
Neuland operates three cGMP manufacturing facilities: Unit-I (Bonthapally), Unit-II (Pashamylaram), and Unit-III (Gaddapotharam). The total reactor volume across these facilities is 12,32,000 liters. The company also boasts a state-of-the-art R&D Centre with 15 development labs, 70 fume hoods, and dedicated labs for peptides. A new research and development center spanning 140,000 square feet is set to open in Hyderabad’s Genome Valley.
Sustainability Framework
The company is committed to Environmental, Social, and Governance (ESG) principles. Key environmental goals include reducing emissions, improving water management, and maintaining Zero Liquid Discharge. Social goals focus on occupational health and safety, diversity and inclusion, and community well-being. Governance commitments include maintaining a strong quality culture, ensuring business continuity, digitalization, and building a sustainable supply chain.
Source: BSE
